3,550 Shares in Penumbra, Inc. $PEN Purchased by Radnor Capital Management LLC

Radnor Capital Management LLC bought a new position in shares of Penumbra, Inc. (NYSE:PEN) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 3,550 shares of the company’s stock, valued at approximately $1,104,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PEN. Holocene Advisors LP purchased a new position in Penumbra during the third quarter worth about $78,585,000. Man Group plc grew its position in Penumbra by 1,862.2% during the second quarter. Man Group plc now owns 206,461 shares of the company’s stock worth $52,984,000 after buying an additional 195,939 shares in the last quarter. AQR Capital Management LLC grew its position in Penumbra by 139.4% during the second quarter. AQR Capital Management LLC now owns 330,990 shares of the company’s stock worth $84,939,000 after buying an additional 192,734 shares in the last quarter. Balyasny Asset Management L.P. purchased a new position in Penumbra during the third quarter worth about $43,476,000. Finally, Stephens Investment Management Group LLC purchased a new position in Penumbra during the fourth quarter worth about $37,563,000. 88.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Penumbra

In other news, Director Harpreet Grewal sold 100 shares of the company’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $328.22, for a total value of $32,822.00. Following the completion of the transaction, the director directly owned 8,719 shares in the company, valued at approximately $2,861,750.18. This represents a 1.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Maggie Yuen sold 2,432 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $342.30, for a total value of $832,473.60. Following the completion of the sale, the chief financial officer directly owned 18,353 shares of the company’s stock, valued at approximately $6,282,231.90. This trade represents a 11.70% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.90% of the stock is currently owned by corporate insiders.

Penumbra Price Performance

PEN opened at $326.26 on Tuesday. The stock has a 50-day moving average price of $330.69 and a 200-day moving average price of $319.70. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $362.41. The company has a current ratio of 6.02, a quick ratio of 3.95 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $12.83 billion, a P/E ratio of 75.17, a PEG ratio of 1.97 and a beta of 0.74.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The firm had revenue of $374.76 million during the quarter, compared to analysts’ expectations of $370.47 million. During the same quarter in the previous year, the company posted $0.83 earnings per share. Penumbra’s revenue for the quarter was up 15.6% compared to the same quarter last year. Equities analysts predict that Penumbra, Inc. will post 5.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Citigroup reduced their target price on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. UBS Group restated a “neutral” rating and set a $374.00 target price on shares of Penumbra in a research report on Thursday, February 26th. Canaccord Genuity Group cut Penumbra from a “buy” rating to a “hold” rating and boosted their target price for the stock from $359.00 to $374.00 in a research report on Tuesday, January 20th. Wall Street Zen upgraded Penumbra to a “hold” rating in a research report on Saturday, May 9th. Finally, Royal Bank Of Canada cut Penumbra from an “outperform” rating to a “sector perform” rating and upped their price objective for the stock from $355.00 to $374.00 in a report on Tuesday, January 20th. Three equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $361.33.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.